News for 4SC AG (VSC.DE)

Published at

Oct 9, 2024 11:40 PM

by gurufocus.com

positive

positive

4SC AG (FRA:VSC) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Release Date: August 08, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points 4SC AG (FRA:VS

VSC.DE

Read more →
Published at

Oct 9, 2024 9:40 PM

by gurufocus.com

positive

positive

Q2 2024 4Sc AG Earnings Call Transcript

Aug 08, 2024 / 01:00PM GMTOperator Hello, everyone, and welcome to the 4Sc AG half year conference call. My name is [Ezra] and I will be coordinating your call

VSC.DE

Read more →
Published at

May 8, 2024 10:27 AM

by marketscreener.com

neutral

neutral

4SC : Information pursuant to Section 125 para. 1 German Stock Corporation Act (AktG) in connection with Section 125 para. 5 AktG, Article 4 para. 1 and Table 3 of the Annex to Implementing Regulation

Annual general meeting of 4SC AG on 20 June 2024 Convenience Translation Information pursuant to section 125 para. 1...

VSC.DE

Read more →
Published at

Mar 8, 2024 11:49 AM

by gurufocus.com

positive

positive

Q3 2023 4Sc AG Earnings Call Transcript

Oct 19, 2023 / 01:00PM GMTOperator Hello, everyone, and welcome to the 4SC AG Q3 Conference Call. My name is Nadia, and I'll be coordinating the call today. (Op

VSC.DE

Read more →
Published at

Mar 8, 2024 11:49 AM

by gurufocus.com

positive

positive

Q2 2022 4Sc AG Earnings Call Transcript

Aug 09, 2022 / 12:00PM GMTJason Loveridge - 4SC AG - Chairman of Management Board, CEO & MD (technical difficulty) I'm sure you've all already seen our press re

VSC.DE

Read more →
Published at

Mar 8, 2024 11:49 AM

by gurufocus.com

positive

positive

Half Year 2021 4Sc AG Earnings Call Transcript

Aug 10, 2021 / 12:00PM GMTOperator Hello, and welcome to the 4SC AG Conference Call Half Year Report. My name is Harry, and I'll be your operator today. (Operat

VSC.DE

Read more →
Published at

Mar 8, 2024 11:49 AM

by gurufocus.com

positive

positive

Q1 2021 4Sc AG Earnings Call Transcript

Apr 20, 2021 / 12:00PM GMTOperator Ladies and gentlemen, welcome to today's 4SC AG Conference Call Q1 Announcement. My name is Lydia, and I'll be coordinating y

VSC.DE

Read more →
Published at

Mar 8, 2024 11:49 AM

by gurufocus.com

positive

positive

Q3 2019 4Sc AG Earnings Call Transcript

Oct 17, 2019 / 12:30PM GMTOperator Hello, and welcome to the 4SC AG 2019 Q3 Announcement. (Operator Instructions) I would now like to hand over to your host, La

VSC.DE

Read more →
Published at

Feb 26, 2024 7:00 PM

by globenewswire.com

mixed

mixed

Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol

The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies,...

VSC.DE PSTX INCY I1NC34.SA GNMSF GMABN.MX GMAB BPTH 0J9P.L 003850.KS TGTX KURA IGMS 0VGI.L

Read more →
Published at

Nov 21, 2023 7:00 PM

by globenewswire.com

mixed

mixed

Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight

The rapid growth in the peripheral T-cell lymphoma market is mainly attributed to the launch of ADCETRIS, along with the robust clinical pipeline and the...

VSC.DE CSPHF KURA

Read more →
Published at

Sep 21, 2022 7:00 PM

by globenewswire.com

mixed

mixed

40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight

Marginal Zone Lymphoma Pipeline constitutes 40+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies,...

VSC.DE NRIX JNJ DJNJ3.BA DJNJ2.BA CLRB BPTH 003850.KS TGTX ONCT MEIP INCY IGMS I1NC34.SA CLDX ACET 0VGI.L 0JW9.L 0J9P.L 0HX7.L

Read more →
Published at

Feb 1, 2021 9:20 AM

by yahoo.com

mixed

mixed

AiCuris Changes its Legal Form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG

Long history of success in fighting infectious diseases - ready for future growthAiCuris has been focusing on the identification and development of novel treatments to fight infectious diseases with high medical needs driven by understanding the indication and selecting the appropriate approach, since the Company was spun-out from Bayer's anti-infective unit in 2006. The Company's first product, Prevymis(R) (letermovir), a novel therapy for human cytomegalovirus (HCMV) infections is revolutionizing transplant medicine.

TCE2.MU TCE2.F TCE2.BE CLDX VSC.SG VSC.MU VSC.HM VSC.F VSC.DU VSC.DE VSC.BE MRK1N.MX MRK.SG MRK.MU MRK.F MRK.DE MRK.BE MKGAF

Read more →